Viridian Therapeutics, Inc.\DE
Business
Viridian Therapeutics is a biopharmaceutical company discovering, developing, and commercializing potential best-in-class medicines for serious and rare autoimmune and rare diseases. The company's pipeline includes IGF-1R antibodies (veligrotug and elegrobart) for thyroid eye disease, FcRn inhibitors for multiple autoimmune disorders, and a TSHR inhibitor program for thyroid eye disease and Graves' disease. Viridian operates through internal research and in-licensing, with commercial infrastructure being built for anticipated product launches. The company holds worldwide commercialization rights (excluding Japan and greater China) to its lead programs and is advancing multiple candidates through clinical development.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 71 | 302,000 | 314,000 | 2 | 3 | |
| Research and development | 339 | 238 | 160 | 101 | 57 | |
| Selling, general and administrative | 95 | 61 | 95 | — | — | |
| Total operating expenses | 434 | 299 | 255 | 136 | 83 | |
| Loss from operations | −363 | −299 | −254 | −134 | −80 | |
| Interest income | 27 | 32 | 18 | — | — | |
| Interest expense | −5 | −2 | −1 | −486,000 | — | |
| Other expense, net | −2 | −314,000 | −193,000 | — | — | |
| Total other income, net | 21 | 29 | 17 | 4 | 315,000 | |
| Net loss | −343 | −270 | −238 | −130 | −79 | |
| Unrealized gain (loss) on available-for-sale securities | 457,000 | −348,000 | 728,000 | — | — | |
| Total other comprehensive income (loss) | 457,000 | −348,000 | 728,000 | −233,000 | −149,000 | |
| Comprehensive loss | −342 | −270 | −237 | −130 | −80 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 212 | 100 | 103 | 156 | 42 | |
| Marketable securities | 662 | 618 | 375 | 269 | 155 | |
| Prepaid expenses and other current assets | 20 | 21 | 9 | 7 | 3 | |
| Total current assets | 894 | 738 | 486 | 431 | 200 | |
| Property and equipment, net | 1 | 1 | 2 | 1 | 375,000 | |
| Operating lease right-of-use assets | 2 | 2 | 2 | 2 | 2 | |
| Other assets | 2 | 501,000 | 604,000 | 982,000 | 1 | |
| Total assets | 899 | 742 | 490 | 435 | 204 | |
| Accounts payable | 9 | 2 | 2 | 14 | 2 | |
| Total accrued liabilities | 62 | 46 | 24 | 19 | 11 | |
| Total current liabilities | 71 | 48 | 27 | 33 | 14 | |
| Long-term debt, net | 50 | 21 | — | — | — | |
| Derivative liability | 20 | 0 | — | — | — | |
| Liability related to the sale of future revenue, net | 34 | 0 | — | — | — | |
| Other liabilities | 2 | 2 | 989,000 | 1 | 1 | |
| Total liabilities | 177 | 71 | 48 | 40 | 16 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Common stock, $0.01 par value; 200,000,000 shares authorized; 101,826,500 and 80,994,046 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 810,000 | 540,000 | 414,000 | 239,000 | |
| Additional paid-in capital | 1,927 | 1,478 | 961 | 741 | 412 | |
| Accumulated other comprehensive income (loss) | 447,000 | −10,000 | 338,000 | −390,000 | −157,000 | |
| Accumulated deficit | −1,339 | −996 | −726 | −488 | −358 | |
| Total stockholders equity | 722 | 672 | 442 | 395 | 188 | |
| Total liabilities and stockholders equity | 899 | 742 | 490 | 435 | 204 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Share-based compensation expense | 44 | 42 | 67 | 20 | 14 | |
| Accretion and amortization of available-for-sale securities | −7 | −16 | −11 | −210,000 | 965,000 | |
| Non-cash interest expense | 3 | 377,000 | 317,000 | — | — | |
| Depreciation and amortization | 500,000 | 500,000 | 500,000 | 300,000 | 100,000 | |
| Issuance costs allocated to derivative liability | 2 | 0 | 0 | — | — | |
| Change in fair value of derivative liability | 700,000 | 0 | 0 | — | — | |
| Issuance of common stock under license agreement | 0 | 0 | 6 | 0 | 8 | |
| Other non cash items | 157,000 | 620,000 | 775,000 | 0 | 0 | |
| Prepaid expenses, other current assets and other assets | 262,000 | −12 | −2 | −3 | −1 | |
| Accounts payable | 7 | −73,000 | −12 | 12 | 2 | |
| Accrued liabilities and other liabilities | 16 | 21 | 5 | 8 | 1 | |
| Net cash used in operating activities | −276 | −232 | −184 | −94 | −55 | |
| Purchases of marketable securities | −579 | −695 | −408 | −223 | −188 | |
| Maturities of marketable securities | 542 | 467 | 315 | 109 | 114 | |
| Purchases of property and equipment | −495,000 | −511,000 | −898,000 | −797,000 | −338,000 | |
| Net cash used in investing activities | −38 | −229 | −94 | −115 | −74 | |
| Proceeds from issuance of common stock in offerings | 289 | 384 | 110 | — | — | |
| Proceeds from the issuance of common stock | 63 | 70 | 15 | 292 | 114 | |
| Proceeds from the issuance of Series B convertible preferred stock in offerings | 0 | 25 | 76 | 44 | 17 | |
| Proceeds from the exercise of warrants | 2 | 0 | 2 | 935,000 | 1 | |
| Proceeds from issuance of long-term debt, net | 29 | 0 | 15 | 5 | — | |
| Payment of debt issuance costs | −478,000 | 0 | −514,000 | −446,000 | 0 | |
| Proceeds from sale of future revenue | 55 | 0 | 0 | — | — | |
| Payment of issuance costs associated with sale of future revenue | −5 | 0 | 0 | — | — | |
| Proceeds from issuance of common stock upon exercise of stock options | 12 | 5 | 19 | 3 | 1 | |
| Proceeds from the issuance of common stock for cash under employee stock purchase plan | 1 | 674,000 | 580,000 | 183,000 | 39,000 | |
| Net cash provided by financing activities | 427 | 458 | 226 | 322 | 125 | |
| Net increase (decrease) in cash and cash equivalents | 113 | −3 | −53 | 113 | −4 | |
| Interest paid | 2 | 2 | 886,000 | 293,000 | 0 | |
| Issuance of common stock upon the conversion of convertible preferred stock | 57 | 41 | 7 | — | — | |
| Right-of-use asset obtained in exchange for new lease liability | 729,000 | 496,000 | 0 | 0 | — | |
| Remeasurement of right-of-use asset and lease liability for lease modifications | 0 | 837,000 | 641,000 | 448,000 | — | |
| Extinguishment of long-term debt | 20 | 0 | 5 | 0 | 0 | |
| Issuance of long-term debt | 20 | 0 | 5 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Viridian Therapeutics, Inc.\DE's CIK number?
Viridian Therapeutics, Inc.\DE's SEC CIK number is 0001590750 (1590750). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Viridian Therapeutics, Inc.\DE's SEC filings?
All of Viridian Therapeutics, Inc.\DE's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Viridian Therapeutics, Inc.\DE last report earnings?
Viridian Therapeutics, Inc.\DE (VRDN) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-205010). This is Viridian Therapeutics, Inc.\DE's most recent earnings filing of record — not a forecast of its next earnings date.
What is Viridian Therapeutics, Inc.\DE's most recent earnings 8-K?
Viridian Therapeutics, Inc.\DE's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-205010. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Viridian Therapeutics, Inc.\DE's latest earnings 8-K →
Look up any company's CIK number →